MA50358A - Sémaglutide en thérapie médicale - Google Patents

Sémaglutide en thérapie médicale

Info

Publication number
MA50358A
MA50358A MA050358A MA50358A MA50358A MA 50358 A MA50358 A MA 50358A MA 050358 A MA050358 A MA 050358A MA 50358 A MA50358 A MA 50358A MA 50358 A MA50358 A MA 50358A
Authority
MA
Morocco
Prior art keywords
semaglutide
medical therapy
therapy
medical
Prior art date
Application number
MA050358A
Other languages
English (en)
French (fr)
Inventor
Thomas Hansen
Maria Kabisch
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60083831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50358(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA50358A publication Critical patent/MA50358A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA050358A 2017-10-12 2018-10-10 Sémaglutide en thérapie médicale MA50358A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17196254 2017-10-12

Publications (1)

Publication Number Publication Date
MA50358A true MA50358A (fr) 2020-08-19

Family

ID=60083831

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050358A MA50358A (fr) 2017-10-12 2018-10-10 Sémaglutide en thérapie médicale

Country Status (18)

Country Link
US (4) US12029779B2 (https=)
EP (1) EP3694538A1 (https=)
JP (2) JP7148605B2 (https=)
KR (1) KR20200069316A (https=)
CN (4) CN120241968A (https=)
AU (2) AU2018348929B2 (https=)
BR (1) BR112020006246A2 (https=)
CA (1) CA3078652A1 (https=)
CL (1) CL2020000812A1 (https=)
IL (3) IL322968A (https=)
MA (1) MA50358A (https=)
MX (3) MX2020003049A (https=)
MY (1) MY204827A (https=)
PH (1) PH12020550185A1 (https=)
SG (1) SG11202002841PA (https=)
TW (1) TWI842681B (https=)
WO (1) WO2019072941A1 (https=)
ZA (3) ZA202503387B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7148605B2 (ja) * 2017-10-12 2022-10-05 ノヴォ ノルディスク アー／エス 医学療法におけるセマグルチド
EP4104820A4 (en) 2020-02-14 2024-04-17 G2GBIO, Inc. Pharmaceutical composition comprising sustained-release microspheres including glp-1 analogue or pharmaceutically acceptable salt thereof
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
EP4313016A4 (en) * 2021-03-29 2025-01-22 Sanford Health METHODS AND COMPOSITIONS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES
AU2023285400A1 (en) * 2022-06-08 2024-12-05 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
WO2024249659A2 (en) * 2023-05-30 2024-12-05 The Medical College Of Wisconsin, Inc. Methods for weight loss and/or reducing weight gain
US12597496B2 (en) * 2023-06-05 2026-04-07 Closed Loop Medicine Ltd. Dosing of incretin pathway drugs

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
AU2002316811A1 (en) 2001-06-28 2003-03-03 Novo Nordisk A/S Stable formulation of modified glp-1
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
TR201906789T4 (tr) 2003-11-20 2019-05-21 Novo Nordisk As Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları.
RU2413530C9 (ru) 2004-11-12 2021-05-18 Ново Нордиск А/С Стабильные препараты инсулинотропных пептидов
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
MX2008013216A (es) 2006-04-14 2008-10-27 Mannkind Corp Formulaciones farmaceuticas de peptido-1 tipo glucagon (glp-1).
EP2481410B1 (en) 2007-01-31 2016-07-13 BIAL - Portela & Ca., S.A. Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime
WO2008116088A1 (en) 2007-03-20 2008-09-25 Nippon Kayaku Kabushiki Kaisha Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
US8748377B2 (en) 2008-12-10 2014-06-10 Glaxosmithkline Llc Pharmaceutical compositions
EP2395988A2 (en) 2009-02-13 2011-12-21 Boehringer Ingelheim International GmbH Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
EP2512518A1 (en) 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
SG191252A1 (en) 2010-12-22 2013-07-31 Marcadia Biotech Inc Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
US20140220134A1 (en) 2011-06-24 2014-08-07 Astrazeneca Pharamceuticals LP Method for treating diabetes with extended release formulation of glp-1 receptor agonists
LT2753312T (lt) 2011-09-08 2017-01-25 Mereo Biopharma 2 Limited Aromatazės inhibitoriaus panaudojimas hipogonadizmo ir susijusių ligų gydymui
JP6250034B2 (ja) * 2012-05-08 2017-12-20 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
NZ727849A (en) 2012-06-29 2018-06-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
HRP20251088T1 (hr) 2012-07-01 2025-11-07 Novo Nordisk A/S Upotreba dugodjelujućih peptida glp‑1
JP6672140B2 (ja) * 2013-05-02 2020-03-25 ノヴォ ノルディスク アー／エス Ｇｌｐ−１化合物の経口投薬
KR102844773B1 (ko) 2015-12-23 2025-08-13 암젠 인크 위 억제 펩티드 수용체 (gipr)에 대한 결합 단백질을 glp-1 효능제와 조합하여 사용하여 대사 장애를 치료하거나 개선시키는 방법
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 糖尿病および関連する状態の処置におけるガボキサドールの使用
JP7148605B2 (ja) 2017-10-12 2022-10-05 ノヴォ ノルディスク アー／エス 医学療法におけるセマグルチド

Also Published As

Publication number Publication date
ZA202503387B (en) 2025-09-25
IL322969A (en) 2025-10-01
CN120241968A (zh) 2025-07-04
ZA202503350B (en) 2025-09-25
MX2025002189A (es) 2025-04-02
JP7475398B2 (ja) 2024-04-26
BR112020006246A2 (pt) 2021-03-30
CN119950682A (zh) 2025-05-09
US20240415935A1 (en) 2024-12-19
TW201914611A (zh) 2019-04-16
AU2018348929B2 (en) 2025-02-27
SG11202002841PA (en) 2020-04-29
US20200237876A1 (en) 2020-07-30
EP3694538A1 (en) 2020-08-19
MX2025002188A (es) 2025-04-02
IL273470A (en) 2020-05-31
AU2025203535A1 (en) 2025-06-05
CL2020000812A1 (es) 2020-08-14
US12295988B2 (en) 2025-05-13
US12029779B2 (en) 2024-07-09
KR20200069316A (ko) 2020-06-16
MX2020003049A (es) 2020-07-27
US12551536B2 (en) 2026-02-17
JP2020536854A (ja) 2020-12-17
MY204827A (en) 2024-09-18
CA3078652A1 (en) 2019-04-18
CN119838000A (zh) 2025-04-18
ZA202503388B (en) 2025-09-25
RU2020114960A (ru) 2021-10-28
TWI842681B (zh) 2024-05-21
IL322968A (en) 2025-10-01
US20240316159A1 (en) 2024-09-26
JP7148605B2 (ja) 2022-10-05
WO2019072941A1 (en) 2019-04-18
US20250235511A1 (en) 2025-07-24
AU2018348929A1 (en) 2020-05-07
RU2020114960A3 (https=) 2022-02-11
PH12020550185A1 (en) 2021-03-01
JP2022132414A (ja) 2022-09-08
CN111212657A (zh) 2020-05-29

Similar Documents

Publication Publication Date Title
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
PL3303632T3 (pl) Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
EP3709882A4 (en) DIAGNOSTIC AND THERAPEUTIC SPLINTS
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
EP3335740C0 (en) Medical hydrogel
DK3474802T3 (da) Medicinsk forbinding
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
MA50358A (fr) Sémaglutide en thérapie médicale
BR112017002074A2 (pt) vestuário e método de compressão médica terapêutica
HUE049479T2 (hu) Hidrofil orvostechnikai eszköz
DK3373874T4 (da) Medicinsk forbinding
EP3723692A4 (en) MEDICAL ASSISTANT
HRP20182134T1 (hr) Triazinski spoj i njegova upotreba u medicinske svrhe
DK3432970T3 (da) In vivo lægemiddelleveringsindretninger
EP3445431A4 (en) PATIENT INTERFACE AND ASPECTS THEREOF
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
IL250692B (en) Medical treatments based on anamorelin
SI3268374T1 (sl) KV1.3 inhibitorji in njihova medicinska uporaba
HUE054998T2 (hu) Kombinációs terápiák emlõrák kezelésében való alkalmazásra
IL264407A (en) Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases
PL2988750T5 (pl) Zastosowanie chlorowodorku landilolu w długotrwałym leczeniu tachyarytmii
DK3325027T3 (da) Medicinsk implantat
ITUA20163417A1 (it) Fat and medical uses thereof
HUE058645T2 (hu) Gyógyszer köszvény kezelésében való felhasználásra